Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia Safety and PK Study of F573 in Healthy Volunteers
NCT04820049Phase 1Completed
- Sponsor
- Gyre Pharmaceuticals
- Start
- Feb 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acute-on-chronic liver failure (ACLF) comparing F573 Group with Placebo Group (2 arms). Primary endpoints: Maximum Tolerated Dose up to 7 days, Maximum Plasma Concentration up to 7 days and 3 more. Started Feb 2021; status: completed.
02
Drugs
F573
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT04820049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04820049.